2011
Chapter 3
Alagille D, Baldwin R, Tamagnan G. Chapter 3. Drug Discovery 2011, 49-143. DOI: 10.1039/9781849732918-00049.Peer-Reviewed Original ResearchBrain pharmacokinetic parametersCNS drug discoveryPost-mortem examinationNuclear imaging techniquesClinical trialsBrain targetsPharmacological challengeBrain pathologyNew therapiesImaging techniquesPharmacokinetic parametersClinical relevanceNeurological disordersBrain functionTherapeutic drugsDisease statesNew drugsDrug developmentDrug discoveryHuman brainVivo observationsComplex organDrugsModern psychiatryTherapy
2009
P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Seibyl J, Zubal G, Tamagnan G, Marek K. P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p265-p265. DOI: 10.1016/j.jalz.2009.04.325.Peer-Reviewed Original ResearchIC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Seibyl J, Zubal G, Tamagnan G, Marek K. IC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development. Alzheimer's & Dementia 2009, 5: p52-p52. DOI: 10.1016/j.jalz.2009.05.099.Peer-Reviewed Original Research